权衡生殖支原体检测与治疗方法的潜在获益与危害
本综述汇总自美国CDC 2015年性传播疾病治疗指南以来发表的证据,系统评估生殖支原体检测与治疗的潜在获益和危害。数据显示大环内酯类耐药常见,氟喹诺酮类耐药正在增加,后遗症数据仍不充分,自然史了解不完整。检测和治疗的潜在获益包括缓解症状、阻断传播和预防后遗症,潜在危害包括费用、患者焦虑和抗菌药物耐药性增加。
要点
- 大环内酯类耐药常见,氟喹诺酮类耐药正在增加
- 后遗症数据仍不充分,自然史了解不完整
- 检测和治疗的潜在获益包括缓解症状、阻断传播和预防后遗症
核心结论
- 本系统综述表明抗菌药物耐药性增加,且对该菌自然史的了解不完整。
研究设计与样本
- 系统综述,汇总自美国CDC 2015年性传播疾病治疗指南以来发表的证据。
主要发现
- 大环内酯类耐药常见,氟喹诺酮类耐药正在增加。
- 后遗症数据仍不充分。
- 检测和治疗的潜在获益包括缓解症状、阻断传播和预防后遗症。
- 潜在危害包括费用、患者焦虑和抗菌药物耐药性增加。
局限性
- 后遗症数据仍不充分。
- 自然史了解不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since Mycoplasma genitalium was identified 40 years ago, much of the epidemiology has been described, diagnostic tests have been developed and approved, and recommended treatment approaches have been identified. However, the natural history remains incompletely understood, and antimicrobial resistance has rapidly increased. This review summarizes evidence published since the US Centers for Disease Control and Prevention 2015 Sexually Transmitted Diseases Treatment Guidelines. Data on sequelae remain insufficient, macrolide resistance is common, and fluoroquinolone resistance is increasing. Potential benefits of testing and treatment include resolving symptoms, interrupting transmission, and preventing sequelae. Potential harms include cost, patient anxiety, and increasing antimicrobial resistance. This systematic review demonstrates increasing antimicrobial resistance and incomplete understanding of the bacterium’s natural history.
引用
- Manhart LE, Geisler WM, Bradshaw CS, et al. Weighing Potential Benefits and Harms of Mycoplasma genitalium Testing and Treatment Approaches. Emerg Infect Dis. 2022. PMID: 35876565. doi:10.3201/eid2808.220094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。